Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
To read the full story
Related Article
- Japan’s Emergency Approval System Comes into Force, Nod Based on Presumed Efficacy
May 23, 2022
- Japan Clears Bill to Create Emergency Approval System, Enforcement Slated by Month-End
May 13, 2022
- Products Filed for Conditional OK Can Be Switched to Emergency Approval: MHLW Official
April 27, 2022
- Upper House Starts Deliberations on PMD Law Amendment Bill
April 25, 2022
- Emergency Approval Plan Clears Lower House Panel; Opposition Bills Rejected, but Some Ideas Make It into Resolution
April 18, 2022
- Shionogi COVID Pill Doesn’t Meet “Presumed Efficacy” Criteria: HSC Subcommittee Chair
April 13, 2022
- Extension of Emergency Approval Period Would Be Allowed Only Once: MHLW Official
April 7, 2022
- Japan PM Touts Proposed Emergency Approval Scheme as Bill Enters Diet Deliberations
April 1, 2022
- PMD Law Amendment Bill to Enter Diet Debate March 31, CDP’s Counter-Legislation Too
March 30, 2022
- Opposition Party Mulls Counter-Legislation against PMD Law Amendment Bill
March 24, 2022
- Japan Cabinet OKs Draft Bill to Amend PMD Law
March 2, 2022
- Bill to Amend PMD Law Set for Cabinet Approval as Early as March 1
February 24, 2022
- LDP Health Committee OKs Bill to Amend PMD Law
February 18, 2022
- LDP Health Committee to Review PMD Law Amendment Bill Mid-February
February 10, 2022
REGULATORY
- Japan Ups Efforts to Better Communicate Pricing, Regulations to Overseas: Official
April 19, 2024
- MHLW Panel Sets Topics for PMD Act Amendment; Pediatrics, Drug Loss on Agenda
April 19, 2024
- Japan Govt Sued for Lack of Information on COVID Vaccine Risks
April 18, 2024
- MOF Ramps Up Push for Use of Cost-Effectiveness Assessment in Reimbursement Decisions
April 17, 2024
- PMDA Stepping Up Generic Compliance Inspections from August Approvals
April 16, 2024
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…